Kumar Neil 4

What Happened Neil Kumar, CEO of BridgeBio Pharma (BBIO), sold a total of 80,000 shares in multiple transactions on March 12–13, 2026, generating roughly $5.50 million in proceeds. The trades were reported as open-market (sale) transactions, with individual trades at prices between approximately $67.76 and $70.18 per share (detailed per-trade prices in the filing). The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted March 31, 2025, indicating pre-scheduled dispositions rather than discretionary, same-day sales.

Key Details

• Dates: March 12–13, 2026 (Form filed March 16, 2026).
• Total shares sold: 80,000; approximate proceeds: $5,501,068.
• Price range reported (per filing footnotes): about $67.76 to $70.18 per share; the filing provides weighted-average ranges and offers to provide per-price breakdowns on request.
• Transaction type: S = Sale (open market/private sale as reported); effected under a Rule 10b5‑1 plan (footnote F1).
• Beneficial ownership note: filing includes a disclaimer (F3) that the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
• Timeliness: Filed March 16, 2026 for trades on Mar 12–13 — reported within the normal Section 16 timing window.

Context Sales under an established 10b5‑1 plan are typically pre-planned and are treated as routine dispositions; they do not necessarily indicate the insider’s current views on the company’s prospects. Retail investors should view this as an insider sale (liquidity) rather than a purchase signal. If you need the exact per-trade price breakdown, the filing indicates the reporting person will provide that information upon request.